{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T14:29:29Z","timestamp":1795098569544,"version":"4.10.3"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.ejca.2005.09.034","type":"journal-article","created":{"date-parts":[[2006,1,24]],"date-time":"2006-01-24T04:52:59Z","timestamp":1138078379000},"page":"456-459","source":"Crossref","is-referenced-by-count":55,"title":["Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level"],"prefix":"10.1016","volume":"42","author":[{"given":"Val\u00e9rie","family":"Boige","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Ta\u00efeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hebbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Malka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Debaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Hannoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Magherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Mignard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Poynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2005.09.034_bib1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference, European Association for the Study of the Liver","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"issue":"5 Suppl. 1","key":"10.1016\/j.ejca.2005.09.034_bib2","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1053\/j.gastro.2004.09.032","article-title":"Chemoembolization for hepatocellular carcinoma","volume":"127","author":"Bruix","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejca.2005.09.034_bib3","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.ejca.2004.02.027","article-title":"Systemic therapy for advanced hepatocellular carcinoma: a review","volume":"40","author":"Nowak","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2005.09.034_bib4","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI119078","article-title":"Selective induction of apoptosis in Hep 3B cells by topoisomerase I inhibitors: evidence for a protease-dependent pathway that does not activate cysteine protease P32","volume":"98","author":"Adjei","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2005.09.034_bib5","first-page":"118","article-title":"Induction of senescent cell-derived inhibitor of DNA synthesis gene (SDI1), in hepatoma (HepG2) cells arrested in the G2-phase of the cycle by 9-nitrocamptothecin","volume":"73","author":"Khaoustov","year":"1995","journal-title":"Lab Invest"},{"key":"10.1016\/j.ejca.2005.09.034_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/1097-0142(20010101)91:1<101::AID-CNCR13>3.0.CO;2-K","article-title":"A phase II study of irinotecan in patients with advanced hepatocellular carcinoma","volume":"91","author":"O\u2019Reilly","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2005.09.034_bib7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00001813-200009000-00009","article-title":"Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11","volume":"11","author":"Gornet","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2005.09.034_bib8","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1200\/JCO.2002.03.123","article-title":"Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction","volume":"20","author":"Raymond","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2005.09.034_bib9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/oxfordjournals.annonc.a059109","article-title":"Population pharmacokinetics of irinotecan (CPT11) and active metabolite SN38 during phase I studies","volume":"6","author":"Chabot","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2005.09.034_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2005.09.034_bib11","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0021-9681(61)90060-1","article-title":"The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent","volume":"13","author":"Gehan","year":"1961","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.ejca.2005.09.034_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1997.15.1.251","article-title":"Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy","volume":"15","author":"Rougier","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2005.09.034_bib13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0959-8049(98)00353-0","article-title":"Clinical activity and benefit of irinotecan (CPT11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)","volume":"35","author":"Van Cutsem","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2005.09.034_bib14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/1389200043335531","article-title":"Cytochrome P450 and liver diseases","volume":"5","author":"Villeneuve","year":"2004","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.ejca.2005.09.034_bib15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000458648","article-title":"Studies of human liver bilirubin-glycosyl transferase. Bilirubin UDP-xylosyl and UDP-glucuronyl transferase activities in diseased human livers","volume":"24","author":"Motoyama","year":"1979","journal-title":"Enzyme"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804905010786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804905010786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T01:58:40Z","timestamp":1555379920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804905010786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0959804905010786"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2005.09.034","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}